John B. Riser, MD
Specialist
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 239
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: University of Alabama School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
AL license 12140
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Alabama Neurology Associates (14 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 239
- Services billed
- 6,404
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 317 | 175 |
| New patient office or other outpatient visit, 45-59 minutes | 38 | 38 |
| Established patient office or other outpatient visit, 40-54 minutes | 32 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Birmingham, AL | 223 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Birmingham, AL | 217 |
| Pregabalin Other prescribers in Birmingham, AL | 132 |
| Prednisone Other prescribers in Birmingham, AL | 130 |
| Baclofen Other prescribers in Birmingham, AL | 116 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Birmingham, AL | 95 |
| Clonazepam Other prescribers in Birmingham, AL | 93 |
| Levetiracetam Other prescribers in Birmingham, AL | 74 |
| Pyridostigmine Bromide Other prescribers in Birmingham, AL | 70 |
| Donepezil Hcl Other prescribers in Birmingham, AL | 69 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 188 payments worth $6,952 in total to this clinician.
| Food and Beverage | $3,971 |
|---|---|
| Consulting Fee | $2,904 |
| Education | $76.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Dec 12, 2025 | Consulting Fee | $2,904 |
| Janssen Biotech, Inc. Dec 10, 2025 | Education in-kind | $76.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $106,629 in research payments for these studies, mostly to the institutions running them.
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi US Services Inc. · Recruiting · NCT06290141 - Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
Sanofi US Services Inc. · Enrolling by invitation · NCT06859099 - Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Genzyme Corporation · Active, not recruiting · NCT05097287
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.